Lipophilic drugs comprise of majority of the active pharmaceutical ingredients which shows the lower oral bioavailability. Many methods have been used to enhance the bioavailability, especially the lipid-based formulations have gained a lot of attention of the researchers, one among the lipid-based formulation approach is the self-emulsifying drug delivery system (SEDDS). SEDDS basically is an isotropic mixture of oils, surfactants and co-surfactants or co-solvents, which after reaching the gastro intestinal tract (GIT) emulsifies itself to emulsion upon mild agitation in the stomach. Solid self-emulsifying drug delivery system (S-SEDDS) is one of advancements in the self-emulsifying systems, which uses the adsorbents where the liquid self-emulsifying system adsorbs and converts itself in to solid, which overcomes the disadvantages of the liquid SEDDS. Various S-SEDDS have been developed in recent years and few of them are, tablets, pellets, microbeads, suppositories, nanoparticles, patches, microspheres etc, without any compromise in the drug release kinetics. These formulations are the cost-effective means of enhancing the bioavailability of the lipophilic drugs.

The aim of the study was to investigate potential of Solid Self Nano-emulsifying Drug Delivery System (SNEDDS) for enhancing solubility and oral bioavailability of Rosuvastatin Calcium (RC). RC solubility was determined in different vehicles such as oils, surfactants and co-surfactants. Capmul MCM (oil), tween 20 (surfactant) and PEG 200 were taken for the preparation of SNEDDS based upon the solubility of RC. Pseudo-ternary phase diagrams were constructed in order to identify efficient self-emulsifying regions. S-SNEDDS were prepared by adsorbing the optimized SNEDDS on to porous polystyrene spheres as a carrier. The S-SNEDDS formulated was free flowing and droplet size of the reconstituted nano-emulsion was almost unchanged after solidification. The prepared S-SNEDDS showed 98.92% release of RC at the end of 60 mins, whereas pure RC exhibited only 38.6%. The C max and AUC 0-t of the S-SNEDDS was about 7.97 and 7.91 fold higher than the pure drug respectively. This research study gives an overview of the S -SNEDDS as a hopeful choice to improve the oral bioavailability of RC.

Background: Cancer is among the leading causes of mortality in India. Studies have reported antineoplastic agents as the common class of drugs causing Adverse Drug Reactions (ADRs). The present study aimed to conduct active surveillance of ADRs of anticancer drugs in the hematology department. Methods: A prospective observational study was conducted in 136 patients with cancer and the incidence and frequency of ADRs were assessed. The study was conducted in 6 months in a multispecialty hospital. Results: Among 136 cancer patients, All was more prevalent (39.70%); CLL, Non- Hodgkin’s Lymphoma were less prevalent (0.73%). ADRs were more prevalent in the Pediatrics department, i.e., 18.53% of ADRs were observed in patients aged <10 years. ADRs in male patients constituted 54.39%, whereas it was 45.60% in female patients. Cytarabine caused the highest number of ADRs (34.48%). The most prevalent ADR was anemia (25.60%). Conclusion: Multiple ADRs were detected in cancer patients. We found that hematological ADRs were more prevalent. Most of the ADRs were possible reactions according to Naranjo and the World Health Organization (WHO) scales.